CENSAVUDINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H12N2O4
Molecular Weight	248.2347
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O

InChI

InChIKey=OSYWBJSVKUFFSU-SKDRFNHKSA-N

InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C12H12N2O4
Molecular Weight	248.2347
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26392486 | https://www.ncbi.nlm.nih.gov/pubmed/26762988 | https://www.ncbi.nlm.nih.gov/pubmed/26340763 | https://www.ncbi.nlm.nih.gov/pubmed/25925234

Censavudine (also known as BMS-986001) is thymidine analogue and nucleosidereverse transcriptase inhibitors developed by Bristol Myers-Squibb for the treatment of HIV infection. In single-cycle assays, Censavudine inhibited HIV-2 isolates from treatment-naive individuals, with 50% effective concentrations (EC50s) ranging from 30 to 81 nM. Censavudine is the first nucleoside analog that, when tested against a diverse collection of HIV-1 and HIV-2 isolates, exhibits more potent activity against HIV-2 than against HIV-1 in culture. In clinical trials Censavudine was generally well tolerated through week 48 and similar efficacy to that of tenofovir disoproxil fumarate

Originator

Approval Year

PubMed

Title	Date	PubMed
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.	2004 May	15105115
Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines.	2006 Dec 28	17181169
Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT.	2007 Mar	17109975
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.	2009 Nov	19704131

Patents

Sample Use Guides

In Vivo Use Guide

100-400 mg/day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 20:16:41 GMT 2023` Edited by `admin` on `Fri Dec 15 20:16:41 GMT 2023`
Record UNII	6IE83O6NGA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CENSAVUDINE

Official Name

English

THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-4'-ETHYNYL-

Systematic Name

English

4'-ETHYNYLSTAVUDINE

Common Name

English

OBP-601

Code

English

censavudine [INN]

Common Name

English

2',3'-DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINE

Systematic Name

English

4'-ED4T

Common Name

English

FESTINAVIR

Common Name

English

BMS-986001

Code

English

1-((2R,5R)-5-ETHYNYL-5-(HYDROXYMETHYL)-2H-FURAN-2-YL)-5-METHYLPYRIMIDINE-2,4-DIONE

Systematic Name

English

CENSAVUDINE, 4'-ETHYNYL-D4T

Common Name

English

CENSAVUDINE [USAN]

Common Name

English

Censavudine [WHO-DD]

Common Name

English

Code System Code Type Description

WIKIPEDIA

FESTINAVIR